ClinicalTrials.gg
Active, not recruitingNCT06453213Updated Oct 27, 2026

Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy

A Phase 4 interventional study of Cenobamate in Focal Onset Seizure, sponsored by SK Life Science, Inc.. Active, not recruiting at 19 sites in United States. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by SK Life Science, Inc. (part of SK Biopharmaceuticals) · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
49
Allocation
Not applicable
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies in Seizures by SK Biopharmaceuticals — 1 open to participants now, 2 under way, 1 of them phase 3. Seizures · SK Biopharmaceuticals.

Enrollment
12th of 15
49 · median 169
Started
2024
the only one that year
Phase 4
Only one
of the 15
Registered
15th of 15
by date

Among the 15 studies in Seizures by SK Biopharmaceuticals, this one is the 12th largest by enrollment, is the only one that started in 2024, is the only one in phase 4, and was the 15th registered.

Seizures

766 studies on the registry are indexed under Seizures; 133 are open to participants now.

Browse Seizures studies →

Open to participants now

1 of the 15 studies in Seizures by SK Biopharmaceuticals is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 92 Seizures studies recruiting now, 36 (39%) set no upper age limit and 43 (47%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Seizures by SK Biopharmaceuticals, or all of them as a file.
02

Study summary

Cenobamate (YKP3089) is a small molecule approved in the United States (US), Europe and several other countries around the world for the treatment of Partial-Onset (focal) seizures in adult subjects (≥18 years of age). In the US it is approved for use as monotherapy, however, there is little clinical data assessing its use as monotherapy in adults with POS. This study is designed to explore the effectiveness of doses of 100 mg/day and 200 mg/day as monotherapy in adult subjects with newly diagnosed or recurrent POS/focal onset epilepsy.

Read the detailed description

This is an uncontrolled, single-arm, open-label, Phase IV study conducted at approximately 40 sites in the US. It will consist of the following Periods:

  1. Pretreatment Period (up to 21 days)
  2. 100 mg/day Treatment Period (6-week Titration Phase, 26-week Maintenance Phase)
  3. 200 mg/day Treatment Period (2-week Titration Phase, 26-week Maintenance Phase)
  4. 26-week Optional Extension Period
  5. Follow Up Period (4 weeks)

Pretreatment Period At the screening visit (Visit 1) the investigator will obtain informed consent and assess the subject for their eligibility to participate in the study. The investigator will review any available hematology, chemistry blood tests, and ECGs. Vital signs and routine physical and neurological exam will be performed.

100 mg/day Treatment Period Subjects who complete screening and meet the inclusion/exclusion criteria begin the 32-week Treatment Period which includes a 6-week Titration Phase and a 26-week Maintenance Phase. During the Titration Phase subjects will be treated with cenobamate 12.5 mg/day for two weeks, 25 mg/day for two weeks and 50 mg/day for two weeks. Subjects tolerating cenobamate at the end of the Titration Phase will continue treatment with 100 mg/day in the Maintenance Phase for 26 weeks. At the end of the Maintenance Phase, the subject will have the option of continuing on in a 26-week Extension Period or discontinuing cenobamate. Subjects who experience a certain type of seizure during the 100 mg/day Maintenance Phase (with or without rescue medication use) will transition to the 200 mg/day Treatment Period.

200 mg/day Treatment Period: The 200 mg/day Treatment Period consists of a 2-week Titration Phase and a 26-week Maintenance Phase. During the 2-week Titration Phase, subjects will receive cenobamate 150 mg/day before entering the 26-week 200 mg/day Maintenance Phase. At the end of the Maintenance Phase, the subject will have the option of continuing on in a 26-week Extension Period or discontinuing cenobamate. If the subject experiences a certain type of seizure at 200 mg/day during the Maintenance Phase, then they will be discontinued from the study.

Optional Extension Period:

An Optional Extension Period will last 26 weeks. During the Optional Extension Period, Visits will occur at 13th week (Day 315/287a, Visit 8/8a) and 26th week (Day 406/378a, Visit 9/9a) to record vital signs and identify adverse events and occurrence of a seizure using a seizure diary. If a certain type of seizure occurs during the Optional Extension Period, the subject will be discontinued from the study.

Follow-up Period:

If a subject prematurely discontinues from the study, is not continuing into the Optional Extension Period or completes the last visit in the Optional Extension Period, cenobamate should either be discontinued or will be titrated down by 50% for two weeks and then discontinued depending on the current dose. A follow-up visit should occur two weeks after the date of cenobamate discontinuation except in specific circumstances.

03

Conditions studied

  • Focal Onset Seizure

Browse trials for

04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be considered reliable and willing to be available for the study period and are able to record seizures and report adverse events (AEs) himself/herself or have a caregiver who can record seizures and report AEs for them.
  2. Male or female subjects 18-74 years of age with a diagnosis of partial-onset seizures (POS) according to the 2017 ILAE Classification of Epileptic Seizures. Diagnosis will be established by clinical history and an electroencephalogram (EEG) consistent with POS. Subjects with a normal EEG could be included provided they met the other diagnostic criteria according to clinical history.
  3. Subjects who are newly diagnosed or have recurrent epilepsy and have experienced:

    1. At least 2 unprovoked seizures (at least >24 hours apart) within the 1 year prior to Day 1 of the Treatment Period, of which, at least 1 unprovoked seizure (but below 20 seizures) occurred in the 12 weeks prior to Day 1 of the Treatment Period.

      OR

    2. 1 unprovoked seizure within the 12 weeks prior to Day 1 of the Treatment Period with concomitant information to support an increased risk (>60%) of a second seizure. In the absence of clear information about recurrence risk, or even knowledge of such information, the default definition of epilepsy originates at the second unprovoked seizure.

    Subjects who are newly diagnosed and have been prescribed a low dose of 1 ASM for ≤12 weeks can be included if the other ASM can be safely down-titrated/discontinued per Investigator discretion within 6 weeks after the 1st dose of cenobamate. For subjects with recurrent epilepsy, they must have at least 6 months after the end of the last ASM treatment but can have been prescribed a low dose of 1 ASM for ≤12 weeks if the other ASM can be safely down-titrated/discontinued per Investigator discretion within 6 weeks after the 1st dose of cenobamate.

  4. Female subjects are either not of , defined as premenarchal, for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), if of childbearing potential, must comply with an acceptable method of during the study, for at least 4 weeks prior to study entry and for 2 weeks after last dose of study drug.
  5. Subject and/or caregiver(s)/legal representative must be willing and able to give informed assent/consent for participation in the study.
  6. Subject and their caregiver must be willing and able (in the investigator's opinion) to comply with all study requirements.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have only simple partial-onset seizures (focal aware seizures) without motor signs.
  2. Subjects who have seizure clusters where individual seizures cannot be counted.
  3. Subjects who present with or have a history of Lennox-Gastaut syndrome.
  4. Subjects who have a history of status epilepticus that required hospitalization within 1 year prior to Day 1 of the Treatment Period.
  5. Subjects who have a history of psychogenic non-epileptic seizures within 2 years prior to Day 1 of the Treatment Period.
  6. Subjects who have a history of active suicidal ideation within the last 6 months or suicide attempt within 2 years prior to Day 1 of Treatment Period.
  7. Evidence of disease (eg, cardiac, respiratory, gastrointestinal, psychiatric, other neurological) that in the opinion of the investigator(s) could affect the subject's safety or interfere with the study assessments.
  8. History of Familial Short syndrome or prior subject diagnosis of Short QT syndrome.
  9. Evidence of clinically significant active renal or hepatic disease.
  10. Subjects taking a strong inducer such as phenytoin, phenobarbital, carbamazepine, or rifampin within 12 weeks prior to the Pretreatment Period unless emergency care was needed due to the subject experiencing status epilepticus, uncontrolled seizures, or clusters of seizures.
  11. Subjects who are taking more than one of the following centrally acting drugs: antipsychotic, antidepressant, or anxiolytic. The dose should be stable for the 12 weeks prior to the Pretreatment Period.
  12. Subjects who have a history of any type of surgery for brain or central nervous system within 1 year prior to the Pretreatment Period.
  13. Subjects who have a history of receiving any ASM (including ASM used as rescue treatment and ASMs used for indications other than epilepsy) for more than 12 weeks in total within 6 months prior to Day 1 of the Treatment Period.
  14. Subjects who have used intermittent rescue medicine on 2 or more occasions within 12 weeks before the Pretreatment Period (1 to 2 doses over a 24-hour period considered one-time rescue).
  15. Subjects who have a history of receiving any ASM polytherapy (> 2 ASMs taken concurrently) during a previous episode of epilepsy.
  16. Previous exposure to cenobamate or sensitivity/allergy to components of the oral tablets.
  17. Subjects who have a history of drug or alcohol dependency or abuse within the last 2 years before the Pretreatment Period.
  18. Subjects who have had multiple drug allergies or a severe drug reaction, including dermatological (eg, DRESS syndrome, Stevens-Johnson syndrome), hematological, or organ toxicity reactions.
  19. Females who are breastfeeding or pregnant or planning to get pregnant in the Pretreatment Period or during the conduct of the study.
  20. Subjects who have participated in a study involving administration of an drug or device within 4 weeks before Visit 1, or within approximately 5 half-lives of the previous investigational compound, whichever is longer.
  21. Subjects with dementia.
  22. Subjects who have seizures due to a progressive CNS condition.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    Cenobamate

    All enrolled subjects will automatically participate in the Cenobamate arm since this is a single-arm study.

    Drug: Cenobamate

Interventions

  • The 100 mg/ day Treatment Period includes a 6-week Titration Phase and a 26-week Maintenance Phase. During the Titration Phase subjects will be treated with cenobamate 12.5 mg/day for two weeks, 25 mg/day for two weeks and 50 mg/day for two weeks. Subjects tolerating cenobamate at the end of the Titration Phase will continue treatment with 100 mg/day in the Maintenance Phase for 26 weeks. If the subject does not experience a certain type of seizure in the 100 mg/day Maintenance Phase, he/she can enter the Optional Extension Period (100 mg/day). The 200 mg/day treatment period consists of a 2-week Titration Phase and a 26-week Maintenance Phase. During the 2-week Titration Phase, subjects will receive cenobamate 150 mg/day before entering the 26-week 200 mg/day Maintenance Phase. If the subject does not experience a certain type of seizure during the 200 mg/day Maintenance Phase, he/she can enter the 26 week Optional Extension Period (200 mg/day).

06

What researchers measure

Primary outcomes

  1. Seizure-freedom during the 26-week Maintenance Phase of the 100 mg/day Treatment Period

    The number (percentage) of subjects with POS who achieved seizure-freedom during the 26-week Maintenance Phase of the 100 mg/day Treatment Period.

    Time frame: 32 weeks

Secondary outcomes

  1. Seizure freedom during each of the 26-week Maintenance Phases

    The number (percentage) of subjects with POS who achieved seizure freedom during each of the 26-week Maintenance Phases regardless of cenobamate dose (last evaluated dose of 100 mg/day or 200 mg/day).

    Time frame: 60 weeks

  2. Time to first seizure onset

    Time to first seizure onset (defined as the period from the first cenobamate dose in the Maintenance Phase to first seizure onset).

    Time frame: 52 weeks

  3. Time to withdrawal from the study

    Time to withdrawal from the study (defined as the period from the first dose of cenobamate in the Maintenance Phase to the date of study withdrawal).

    Time frame: 86 weeks

  4. Number (percentage) of subjects with POS who achieved seizure freedom during the 52-week treatment

    The number (percentage) of subjects with POS who achieved seizure freedom during the 52-week treatment (ie, 26-week Maintenance Phase plus Optional 26-week Extension Period).

    Time frame: 52 weeks

Other outcomes

  1. Seizure-freedom rate/time to seizure by POS type

    Seizure-freedom rate/time to seizure by POS type will be analyzed.

    Time frame: 86 weeks

07

Study locations

19 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for May 2027, 31 months after the start.

Of 26 phase 4 interventional studies under Seizures, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 42. This study's planned 31 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2024
First posted
Jun 11, 2024
StartActual
Oct 14, 2024
Primary completionEst.
May 26, 2027
CompletionEst.
Jul 9, 2027
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06453213
Responsible party
Sponsor
First posted
Jun 11, 2024
Start date
Oct 14, 2024
Primary completion
May 26, 2027 (estimated)
Completion
Jul 9, 2027 (estimated)
Last update
Oct 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cenobamate

Start the discussion